Cargando…

Long-term treatment with budesonide/formoterol attenuates circulating CRP levels in chronic obstructive pulmonary disease patients of group D

BACKGROUND: The systemic inflammation is associated with clinical outcome and mortality in chronic obstructive pulmonary disease (COPD) patients. To investigate the effects of tiotropium (Tio) and/or budesonide/formoterol (Bud/Form) on systemic inflammation biomarkers in stable COPD patients of grou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Yi-Hua, Liao, Xi-Ning, Fan, Li-Li, Qu, Yue-Jin, Cheng, De-Yun, Shi, Yong-Hong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568104/ https://www.ncbi.nlm.nih.gov/pubmed/28832630 http://dx.doi.org/10.1371/journal.pone.0183300

Ejemplares similares

Comparative Efficacy of Budesonide/Formoterol with Budesonide, Formoterol or Placebo for Stable Chronic Obstructive Pulmonary Disease: A Meta-Analysis
por: Tang, Bin, et al.
Publicado: (2019)

Therapeutic comparison of a new budesonide/formoterol pMDI with budesonide pMDI and budesonide/formoterol DPI in asthma
por: Morice, A H, et al.
Publicado: (2007)

The rapid effects of budesonide plus formoterol in patients with obstructive airway diseases
por: Bayiz, Hulya, et al.
Publicado: (2015)

Efficacy of budesonide/formoterol and tiotropium combination for the treatment of Chinese patients with chronic obstructive pulmonary disease
por: Feng, Jun-fei, et al.
Publicado: (2018)

A Multicenter, Observational, Prospective Study of the Effectiveness of Switching from Budesonide/Formoterol Turbuhaler(®) to Budesonide/Formoterol Easyhaler(®)
por: Syk, Jörgen, et al.
Publicado: (2019)

Correction to: A Multicenter, Observational, Prospective Study of the Effectiveness of Switching from Budesonide/Formoterol Turbuhaler(®) to Budesonide/Formoterol Easyhaler(®)
por: Syk, Jörgen, et al.
Publicado: (2019)

Budesonide–formoterol (inhalation powder) in the treatment of COPD
por: Ceylan, Erkan
Publicado: (2006)

Comparison of Aerosol Formulations of Formoterol Fumarate and Budesonide
por: Nirale, N. M., et al.
Publicado: (2011)

Budesonide/Glycopyrronium/Formoterol: A Review in COPD
por: Heo, Young-A
Publicado: (2021)

Protocol: Influence of Budesonide and Budesonide/Formoterol on Asthma Control in Smoking Asthmatic Adults
por: Boulet, Louis-Philippe, et al.
Publicado: (2010)

Real-world effectiveness evaluation of budesonide/formoterol Spiromax for the management of asthma and chronic obstructive pulmonary disease in the UK
por: Voorham, Jaco, et al.
Publicado: (2018)

Efficacy and safety of tiotropium bromide combined with budesonide/formoterol in the treatment of moderate to severe chronic obstructive pulmonary disease
por: Zhao, Daguo, et al.
Publicado: (2018)

Real-world evidence effect of budesonide+formoterol Spiromax on patients with asthma and chronic obstructive pulmonary disease in Sweden
por: Janson, Christer, et al.
Publicado: (2019)

The Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol in the Treatment of COPD in the Elderly
por: Guo, Min, et al.
Publicado: (2022)

Budesonide/formoterol combination in COPD: a US perspective
por: Sharafkhaneh, Amir, et al.
Publicado: (2010)

Tolerability of budesonide/formoterol in patients of Kazakhstan rural regions
por: Nurpeissov, Tair, et al.
Publicado: (2015)

Correction to: Budesonide/Glycopyrronium/Formoterol: A Review in COPD
por: Heo, Young-A
Publicado: (2021)

Long-term maintenance of pediatric asthma: focus on budesonide/formoterol inhalation aerosol
por: Huynh, Peter N, et al.
Publicado: (2010)

Long-term safety of budesonide/formoterol for the treatment of elderly patients with bronchial asthma
por: KAGOHASHI, KATSUNORI, et al.
Publicado: (2014)

Correction: Real-world effectiveness evaluation of budesonide/formoterol Spiromax for the management of asthma and chronic obstructive pulmonary disease in the UK
Publicado: (2019)

Correction: Real-world effectiveness evaluation of budesonide/formoterol Spiromax for the management of asthma and chronic obstructive pulmonary disease in the UK
Publicado: (2018)

Characteristics of initiators of budesonide/glycopyrrolate/formoterol for treatment of chronic obstructive pulmonary disease (COPD) in the United States: the AURA study
por: Portillo, Edward C., et al.
Publicado: (2023)

Budesonide/formoterol and formoterol provide similar rapid relief in patients with acute asthma showing refractoriness to salbutamol
por: Bateman, ED, et al.
Publicado: (2006)

Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations
por: Kuna, P, et al.
Publicado: (2007)

Effect of adjusting the combination of budesonide/formoterol on the alleviation of asthma symptoms
por: Souma, Ryosuke, et al.
Publicado: (2018)

Risks of budesonide/formoterol for the treatment of stable COPD: a meta-analysis
por: Tang, Bin, et al.
Publicado: (2019)

Triple Therapy with Budesonide/Glycopyrrolate/Formoterol Fumarate Improves Inspiratory Capacity in Patients with Asthma-Chronic Obstructive Pulmonary Disease Overlap
por: Ishiura, Yoshihisa, et al.
Publicado: (2020)

A randomized, double-blinded, double-dummy efficacy and safety study of budesonide–formoterol Spiromax® compared to budesonide–formoterol Turbuhaler® in adults and adolescents with persistent asthma
por: Virchow, J. Christian, et al.
Publicado: (2016)

The efficacy of adding budesonide/formoterol to ipratropium plus theophylline in managing severe chronic obstructive pulmonary disease: an open-label, randomized study in China
por: Huang, Kewu, et al.
Publicado: (2019)

Budesonide/formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD A double-blind, randomised, non-inferiority, parallel-group, multicentre study
por: Ställberg, Björn, et al.
Publicado: (2009)

Budesonide and formoterol effects on rhinovirus replication and epithelial cell cytokine responses
por: Bochkov, Yury A, et al.
Publicado: (2013)

Early efficacy of budesonide/formoterol in patients with moderate-to-very-severe COPD
por: Calverley, Peter M, et al.
Publicado: (2016)

Retracted: The Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol in the Treatment of COPD in the Elderly
por: Imaging, Contrast Media & Molecular
Publicado: (2023)

Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study
por: Martinez, Fernando J., et al.
Publicado: (2021)

Budesonide and Formoterol Reduce Early Innate Anti-Viral Immune Responses In Vitro
por: Davies, Janet M., et al.
Publicado: (2011)

A scintigraphy study of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler in patients with moderate-to-very severe chronic obstructive pulmonary disease
por: Usmani, Omar, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Triple Therapy with Budesonide/ Glycopyrronium/ Formoterol Fumarate versus Dual Therapy in Patients with Chronic Obstructive Pulmonary Disease in Spain
por: Trigueros, Juan Antonio, et al.
Publicado: (2022)

Evaluation of inhaler technique and achievement and maintenance of mastery of budesonide/formoterol Spiromax® compared with budesonide/formoterol Turbuhaler® in adult patients with asthma: the Easy Low Instruction Over Time (ELIOT) study
por: Price, David B., et al.
Publicado: (2018)

Bronchodilatory effect of inhaled budesonide/formoterol and budesonide/salbutamol in acute asthma: a double-blind, randomized controlled trial
por: Arun, Jenish J, et al.
Publicado: (2012)

Exposure-Response and Clinical Outcome Modeling of Inhaled Budesonide/Formoterol Combination in Asthma Patients
por: Back, Hyun-moon, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_tu02echom5kadht0gibaghg1gl